News »May 2006

Sanofi-Aventis' Acomplia (Rimonabant) concerns perhaps continue

According to an analyst for Morgan Stanley, concerns over the safety look of weight-loss drug Acomplia (Rimonabant) set to continue until the drug is firmly established on the market.

As sources said that in a recent seminar some scientist pointed the data which had shown that patients treated with Acomplia in some of the clinical trials of the drug experienced less "joy" than patients on placebo.

This report adds to concerns about Acomplia drug that affects receptors in the brain and also focus on the 2.7-fold higher rate of psychiatric disorders reported in clinical trials among those receiving Acomplia vs. the placebo.

The FDA panel for the consideration of Acomplia drug has cancelled all meeting scheduled until November.

Read the complete news story here:
http://www.acompliareport.com/News/news-051806.htm